Background: Relapse of CML on imatinib is most often associated with point mutations in the BCR-ABL kinase domain. BMS-354825 is a novel ABL kinase inhibitor with = 300-fold greater potency than imatinib and preclinical activity against 14 of 15 imatinib resistant BCR-ABL mutants tested. Unlike imatinib, BMS-354825 binds the ABL kinase domain in both active and inactive conformations, and is thus predicted to have significant activity in most imatinib-resistant CML and Ph+ ALL cases.
 


[BMS354825]
A group for the BMS354825 clinical trial
A group of CMLHope.Com
Subscribe: [EMAIL PROTECTED]
Web Site: http://groups.cmlhope.com
[CML]
A group of CMLHope.Com
Subscribe: [EMAIL PROTECTED]
Web Site: http://groups.cmlhope.com 

Reply via email to